Dr. Licht is the Johanna Dobe Professor of Medicine, Chief, Division of Hematology/Oncology and an Associate Director (Clinical Sciences) of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. For over 20 years, Dr. Licht's laboratory has studied aberrant transcriptional regulation as a cause of hematological malignancy. This has included the molecular biology of acute promyelocytic leukemia and transcriptional mechanisms and targets of the PLZF transcription factor. He has studied chromatin changes and gene expression mediated by the MMSET protein overexpressed in a subset of multiple myeloma, as well as aberrant gene and miRNA regulation in myeloproliferative neoplasms, and most recently chromatin changes mediated by EZH2 in lymphoma. Dr. Licht is the Principal Investigator of a Leukemia Society Specialized Center of Excellence grant on chromatin mechanisms in hematological malignancies and Senior Scientific Leader of the Northwestern University NCI-Funded Physical Sciences Oncology Center, also centered on aberrant chromatin regulation. Dr. Licht is a Senior Editor of Clinical Cancer Research and serves on the editorial boards of Oncogene, Clinical Epigenetics and Cancer Biology and Therapy. Dr. Licht is a member of the Basic Sciences Committee of the NCI Board of Scientific Counselors.
How did you first hear about nanoHUB?
What is the primary purpose of your visit to nanoHUB?